A Study to Assess the Bioequivalence of Famotidine/Antacid Combination Tablets Compared to Famotidine/Antacid EZ Chew Tablets (0208C-145)(COMPLETED)

Johnson & Johnson Consumer and Personal Products Worldwide24 enrolled

Overview

A study in 24 healthy subjects to assess the bioequivalence of Famotidine/Antacid EZ Chew tablet taken without water and with water compared to the Famotidine/Antacid tablet taken with water. Subjects will be given a single dose of each treatment separated by 5 to 7 days.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Heartburn

Interventions

famotidine (+) calcium carbonate (+) magnesium hydroxide tabletDRUG

A single dose of famotidine/antacid tablet with 120 mL of water in one of three treatment periods

Comparator: famotidine (+) calcium carbonate (+) magnesium hydroxide EZ Chew tablet without waterDRUG

A single dose of famotidine/antacid combination EZ Chew tablet without water in one of three treatment periods

Comparator: famotidine (+) calcium carbonate (+) magnesium hydroxide EZ Chew tablet with waterDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 45 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Female subject is not pregnant or lactating, Females of childbearing potential must use reliable means of contraception during the course of the study * Subject is in good health * Subject is able to abstain from smoking during the 24-hour periods before and during each treatment day Exclusion Criteria: * Subject has a history of stomach ulcers, other Gastrointestinal (GI) diseases or GI surgery * Subject has a history of asthma or severe allergies to drugs or foods * Subject currently uses prescribed or nonprescribed drugs on a regular basis * Subject has a recent history of drug/alcohol abuse * Subject consumes more than 6 cups of coffee per day * Subject has unconventional or extreme dietary habits * Subject has donated blood or has been in a clinical trial in which they received an investigational drug during the past 30 days * Subject has a history of allergy or intolerance to antacids * Female subject is known to be pregnant or is not using reliable means of contraception

Outcomes

Primary Outcomes

Area Under the Curve (AUC(0 to Infinity)) Following Single Dose Administration of Famotidine/Antacid Combination EZ Chew Without Water and Famotidine/Antacid Tablet With Water

Time frame: Through 24 hours post-dose (½, 1, 1 ½, 2, 2 ½, 3, 4, 6, 8, 10, 12, 14, 24 hours post-dose)

Peak Plasma Concentration (Cmax) of Famotidine Following Single Dose Administration of Famotidine/Antacid Combination EZ Chew Without Water and Famotidine/Antacid Tablet With Water

Time frame: Through 24 hours post-dose (½, 1, 1 ½, 2, 2 ½, 3, 4, 6, 8, 10, 12, 14, 24 hours post-dose)

Secondary Outcomes

Area Under the Curve (AUC(0 to Infinity)) Following Single Dose Administration of Famotidine/Antacid Combination EZ Chew With Water and Famotidine/Antacid Tablet With Water

Time frame: Through 24 hours post-dose (½, 1, 1 ½, 2, 2 ½, 3, 4, 6, 8, 10, 12, 14, 24 hours post-dose)

Peak Plasma Concentration (Cmax) of Famotidine Following Single Dose Administration of Famotidine/Antacid Combination EZ Chew With Water and Famotidine/Antacid Tablet With Water

Time frame: Through 24 hours post-dose (½, 1, 1 ½, 2, 2 ½, 3, 4, 6, 8, 10, 12, 14, 24 hours post-dose)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.